Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

• the present invention relates to the use of a pyrazole-derived cannabinoid CB1 receptor antagonist compound for the preparation of medicaments useful in the prevention and treatment of renal diseases.
• Renal diseases include diabetic nephropathies, chronic renal failure, end-stage kidney disease, renal hypertrophy, renal hyperplasia, glomerulosclerosis, glomerulonephritis.
• a cannabinoid receptor antagonist derived from pyrazole means a compound chosen from N-piperidino-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4-methylpyrazole-3-one. carboxamide whose international nonproprietary name is rimonabant, described in European Patent 656354 and N-piperidino-5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4-ethylpyrazole
• a pyrazole-derived cannabinoid CB 1 receptor antagonist selected from rimonabant and N-iperidino-5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4-ethyl pyrazole -3-carboxamide, protects renal function.
• an antagonist compound j CB cannabinoid receptors derived from pyrazole chosen from rimonabant and N-piperidino
• 5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide can be used for the preparation of medicaments useful for preventing and treating renal diseases.
• compositions according to the present invention contain an effective dose of a cannabinoid CBJ receptor antagonist compound, derived from pyrazole, selected from rimonabant and N-piperidino-5- (4-bromophenyl) -1- (2,4 dichloro-phenyl) -4-ethyl pyrazole-3-carboxamide, as well as at least one pharmaceutically acceptable excipient.
• a cannabinoid CBJ receptor antagonist compound derived from pyrazole, selected from rimonabant and N-piperidino-5- (4-bromophenyl) -1- (2,4 dichloro-phenyl) -4-ethyl pyrazole-3-carboxamide, as well as at least one pharmaceutically acceptable excipient.
• Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.
• the active ingredient may be administered in unit dosage form.
• Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal forms of administration. by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants.
• the compounds according to the invention can be used in creams, gels, ointments or lotions.
• capsules or tablets are preferred. More particularly, capsules or tablets containing rimonabant are preferred at a dose of between 5 and 50 mg, more particularly at doses of 5 and 20 mg.
• a cannabinoid receptor antagonist derived from pyrazole, selected from rimonabant and N-piperidino-5- (4-bromophenyl) -1- (2,4-dichlorophenyl) 4-ethylpyrazole-3-carboxamide may be combined with another active ingredient chosen from one of the following therapeutic classes:
• an AT1 receptor antagonist of angiotensin II alone or in combination with a diuretic an AT1 receptor antagonist of angiotensin II alone or in combination with a diuretic
• beta-blocker alone or in combination with a diuretic or a calcium antagonist
• another antihypertensive agent such as an alpha-adrenergic agonist
• lipid-lowering agent or a cholesterol-lowering agent a lipid-lowering agent or a cholesterol-lowering agent
• - an antidiabetic a lipid-lowering agent or a cholesterol-lowering agent
• the present invention also relates to the use of pharmaceutical compositions containing in combination a cannabinoid CBJ receptor antagonist, derived from pyrazole, selected from rimonabant and N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide, and another active ingredient chosen from the active ingredients of one of the following therapeutic classes: an antagonist of the ATi receptors of angiotensin II, alone or in combination diuretic or calcium antagonist;
• antihypertensive agent such as an alpha-adrenergic agonist; a beta-blocker alone or in combination with a diuretic or a calcium antagonist;
• an antihyperlipidemic agent or an antihypercholesterolemic agent an antihyperlipidemic agent or an antihypercholesterolemic agent
• Another anti-obesity agent for the preparation of medicaments useful in the treatment and prevention of renal diseases.
• angiotensin II AT1 receptor antagonist is meant a compound such as candesartan cilexitil, eprosartan, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, valsartan, each of these compounds may itself be associated with a diuretic such as hydrochlorothiazide.
• inhibitor of the conversion enzyme is meant a compound such as alacepril, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, temocapril, trandolapril, zofenopril, each such compounds may itself be associated with a diuretic such as hydrochlorothiazide or indapamide or a calcium antagonist such as amlodipine, diltiazem, felodipine or verapamil.
• a diuretic such as hydrochlorothiazide or indapamide
• a calcium antagonist such as amlodipine, diltiazem, felodipine or verapamil.
• calcium antagonist is meant a compound such as amlodipine, aranidipine, benidipine, bepridil, cilnidipine, diltiazem, efonidipine hydrochloride ethanol, fasudil, felodipine, isradipine, lacidipine, lercanidipine hydrochloride, manidipine, mibefradil hydrochloride, nicardipine, nifedipine, nilvadipine, nimodipine, Nisoldipine, Nitrendipine, Terodiline, Verapamil.
• beta-blocker is meant a compound such as acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol, bevololol, bisoprolol, bopindolol, bucumolol, bufetolol, bunitrolol, butofilolol, carazolol, cardolol, carvedilol, cloranolol, epanolol, esmolol.
• an antihypertensive agent such as an alpha-adrenergic agonist
• a compound such as clonidine, rilmenidine, maxonidine, methyldopa, guanfacine.
• diuretic means a compound such as hydrochlorothiazide, bendroflumethiazide, chlortalidone, cicletanine, indapamide, xipamide.
• hypomipemic or hypocholesterolemic is meant a compound selected from fibrates such as alufibrate, beclobrate, bezafibrate, ciprofibrate, clinofibrate, clofibrate, etofibrate, fenofibrate; statins (HMG-CoA reductase inhibitors), such as atorvastatin, fluvastatin sodium, lovastatin, pravastatin, rosuvastatin, simvastatin, or a compound such as acipimox, aluminum nicotinate, azacosterol, cholestyramine, dextrothyroxine, meglutol, niceritrol, nicoclonate, nicotinic acid , beta-sitosterin, tiadenol.
• statins HMG-CoA reductase inhibitors
• atorvastatin fluvastatin sodium, lovastatin
• antidiabetic means a compound belonging to one of the following classes: sulfonylureas, biguanidines, alpha glucosidase inhibitors, thiazolidinedione, methaglinides, such as acarbose, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide , glimepiride, glipidide, gliquidone, glisoxepide, glybuzole, glymidine, metahexamide, metformin, miglitol, nateglinide, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone, voglibose.
• sulfonylureas biguanidines
• alpha glucosidase inhibitors such as acarbose, aceto
• anti-obesity agent a compound such as amfepramone, benfluorex, benzphetamine, indanorex, mazindole, mefenorex, methamphetamine, D-norpseudoephedrine, orlistat, sibutramine or other cannabinoid CB 1 receptor antagonist.
• the present invention relates to the use of a pharmaceutical composition containing in combination rimonabant and an AT1 receptor antagonist of angiotensin II, including irbesartan, losartan or valsartan.
• the subject of the present invention is the use of a pharmaceutical composition containing in combination rimonabant and irbesartan or N-piperidino-5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide and irbesartan, and use of a pharmaceutical composition containing in combination rimonabant, irbesartan and hydrochlorothiazide or N-piperidino-5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4-ethylpyrazole-3- carboxamide, irbesartan and hydrochlorothiazide.
• the subject of the present invention is the use of a pharmaceutical composition containing, in combination, rimonabant and simvastatin for the preparation of medicaments useful for the prevention and treatment of renal diseases.
• the cannabinoid receptor antagonist derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4 ethylpyrazole-3-carboxamide, and the other associated active ingredient can be administered simultaneously, separately or spread over time.
• Extended use over time is understood to mean the sequential administration of the first compound of the composition according to the invention, included in a pharmaceutical form, then, of the second compound of the composition according to the invention, included in a form pharmaceutical industry.
• the lapse of time elapsed between the administration of the first compound of the composition according to the invention and the administration of the second compound of the same composition according to the invention does not exceed usually not 24 hours, it may be higher if either compound is presented in a pharmaceutical formulation allowing, for example, a weekly administration.
• the pharmaceutical forms comprising either only one of the constituent compounds of the composition according to the invention or the combination of the two compounds, or, where appropriate, of three compounds, which can be used in the various types of uses described above. above, may for example be suitable for oral, nasal, parenteral or transdermal administration.
• the invention therefore also relates to the use for the treatment and prevention of renal disease of a kit containing an antagonist of CBi cannabinoid receptor pyrazole derivative, chosen from rimonabant and N-piperidino-5- (4- bromophenyl) - 1 - (2,4-dichlorophenyl) -4-ethylpyrazole-3 - carboxamide, and another active ingredient or, where appropriate, two combined active ingredients wherein said antagonist of CBi cannabinoid receptor derived from pyrazole, and said active ingredient or, where appropriate, two associated active ingredients are in separate compartments and in similar or different packages, and are intended to be administered simultaneously, separately or spread over time.
• an antagonist of CBi cannabinoid receptor pyrazole derivative chosen from rimonabant and N-piperidino-5- (4- bromophenyl) - 1 - (2,4-dichlorophenyl) -4-ethylpyrazole-3 - carboxamide,
• EXAMPLE 1 Action of rimonabant on the protection of renal function in obese rats. The effect of long-term (12 months) treatment with rimonabant was studied in Zucker rats with established obesity.
• the fa / fa strain of Zucker obese rats is characterized by hyperphagia, obesity, dyslipidemia and type 2 diabetes resulting in the progressive development of nephropathy.
• vehicle-treated Zucker fa / fa obese rats showed marked renal hypertrophy and severe renal failure.
• the deterioration of renal function results in a marked increase in plasma levels of urea and creatinine and a marked reduction in creatinine clearance.
• the elevation of plasma levels of urea and creatinine was decreased in a dose-dependent manner. dependent, and that the clearance of creatinine is partially restored.
• renal hypertrophy was significantly reduced in the group of rats treated with rimonabant.
• rimonabant on renal function occurs without hemodynamic changes.
• mean arterial pressure, left ventricular pressure, heart rate and contractility remain unchanged.
• rimonabant at 3 and 10 mg / kg / day per os has a very significant prolongation of the survival of obese Zucker fa / fa rats.
• mortality was 64% in the Zucker fa / fa untreated obese group, whereas it was limited to 20% (p ⁇ 0.01) and 28% (p ⁇ 0.05). in obese Zucker rats treated with rimonabant at 10 and 3 mg / kg / day, respectively.
• a group of untreated obese Zucker fa / fa rats were also formed, receiving the same amount of food as the 10 mg / kg / day bone group (fed-fed group).
• This Zucker fa / fa obese / pair-fed group has a mortality of 32

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Urology & Nephrology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=36603585

Family Applications (1)

Country Status (18)

Families Citing this family (2)

Family Cites Families (6)

• 2005
  • 2005-05-12 FR FR0504798A patent/FR2882263B1/fr not_active Expired - Fee Related
• 2006
  • 2006-02-17 KR KR1020077019170A patent/KR20070104916A/ko not_active Application Discontinuation
  • 2006-02-17 AU AU2006217794A patent/AU2006217794A1/en not_active Abandoned
  • 2006-02-17 EP EP06709339A patent/EP1855675A1/fr not_active Withdrawn
  • 2006-02-17 EA EA200701800A patent/EA011655B1/ru not_active IP Right Cessation
  • 2006-02-17 BR BRPI0607894-0A patent/BRPI0607894A2/pt not_active IP Right Cessation
  • 2006-02-17 JP JP2007556630A patent/JP2008531526A/ja not_active Withdrawn
  • 2006-02-17 MX MX2007009995A patent/MX2007009995A/es active IP Right Grant
  • 2006-02-17 CA CA002597802A patent/CA2597802A1/fr not_active Abandoned
  • 2006-02-17 WO PCT/FR2006/000369 patent/WO2006090047A1/fr active Application Filing
  • 2006-02-21 AR ARP060100612A patent/AR054003A1/es unknown
  • 2006-02-22 TW TW095105981A patent/TW200640458A/zh unknown
• 2007
  • 2007-07-20 CR CR9270A patent/CR9270A/es not_active Application Discontinuation
  • 2007-07-24 TN TNP2007000291A patent/TNSN07291A1/en unknown
  • 2007-08-02 US US11/832,861 patent/US7622488B2/en not_active Expired - Fee Related
  • 2007-08-09 IL IL185165A patent/IL185165A0/en unknown
  • 2007-08-23 MA MA30159A patent/MA29263B1/fr unknown
  • 2007-09-18 NO NO20074768A patent/NO20074768L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events